PL3385284T3 - Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie - Google Patents

Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie

Info

Publication number
PL3385284T3
PL3385284T3 PL18157667T PL18157667T PL3385284T3 PL 3385284 T3 PL3385284 T3 PL 3385284T3 PL 18157667 T PL18157667 T PL 18157667T PL 18157667 T PL18157667 T PL 18157667T PL 3385284 T3 PL3385284 T3 PL 3385284T3
Authority
PL
Poland
Prior art keywords
antibodies
quetiapine haptens
quetiapine
haptens
Prior art date
Application number
PL18157667T
Other languages
English (en)
Inventor
Eric Hryhorenko
Banumathi Sankaran
Thomas R. DECORY
Theresa TUBBS
Linda COLT
Bart M. REMMERIE
Rhys Salter
Matthew Garrett DONAHUE
Yong Gong
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3385284T3 publication Critical patent/PL3385284T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18157667T 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie PL3385284T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261691598P 2012-08-21 2012-08-21
EP13830990.1A EP2888286B1 (en) 2012-08-21 2013-08-20 Antibodies to quetiapine haptens and use thereof
EP18157667.9A EP3385284B1 (en) 2012-08-21 2013-08-20 Antibodies to quetiapine haptens and use thereof
PCT/US2013/055830 WO2014031665A1 (en) 2012-08-21 2013-08-20 Antibodies to quetiapine haptens and use thereof

Publications (1)

Publication Number Publication Date
PL3385284T3 true PL3385284T3 (pl) 2020-09-21

Family

ID=50148312

Family Applications (3)

Application Number Title Priority Date Filing Date
PL18157667T PL3385284T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL13830990T PL2888286T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL20152974.0T PL3663317T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL13830990T PL2888286T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL20152974.0T PL3663317T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie

Country Status (10)

Country Link
US (3) US9850318B2 (pl)
EP (3) EP3385284B1 (pl)
JP (2) JP6450314B2 (pl)
CN (2) CN110054693A (pl)
AU (2) AU2013305904B2 (pl)
CA (1) CA2882597C (pl)
ES (3) ES2935460T3 (pl)
PL (3) PL3385284T3 (pl)
PT (3) PT3385284T (pl)
WO (1) WO2014031665A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984487B1 (en) * 2005-08-03 2022-10-12 Astellas Institute for Regenerative Medicine Improved methods of reprogramming animal somatic cells
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
AU2013305887B2 (en) 2012-08-21 2018-02-22 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
AU2013305895B2 (en) 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
WO2014031665A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine haptens and use thereof
CN108368180B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN111808046B (zh) * 2020-06-30 2022-11-11 杭州同舟生物技术有限公司 一种喹硫平人工半抗原、人工抗原及其制备方法和应用
CN115073492B (zh) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 一种奥氮平衍生物抗原、奥氮平抗体及其应用
CN116354904B (zh) * 2023-04-26 2023-08-01 北京丹大生物技术有限公司 一种喹硫平衍生物半抗原、抗原、抗喹硫平抗体及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
DK0582368T3 (da) 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
JPH10504186A (ja) 1994-06-10 1998-04-28 オクラホマ メディカル リサーチ ファウンデーション プロテインｃに対するカルシウム結合組換え抗体
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
WO1998059233A1 (en) 1997-06-23 1998-12-30 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
ATE492565T1 (de) * 2002-01-31 2011-01-15 Randox Lab Ltd Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
EP1485130A4 (en) 2002-02-21 2006-11-22 Univ Duke REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
BR0308214A (pt) 2002-03-04 2005-05-10 Amcol International Corp Papel e materiais e processos para a sua produção
WO2003082877A1 (en) 2002-03-28 2003-10-09 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
WO2004011031A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
WO2004014895A1 (en) 2002-08-05 2004-02-19 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US7772240B2 (en) * 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
ATE452882T1 (de) 2003-09-23 2010-01-15 Fermion Oy Herstellung von quetiapin
JP4976134B2 (ja) 2003-10-01 2012-07-18 アドラー コーポレーション スピロ環複素環誘導体及びそれらを使用する方法
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
AU2004298660B2 (en) * 2003-12-12 2010-04-22 Abbott Rapid Diagnostics International Unlimited Company Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
US7087699B2 (en) 2004-05-17 2006-08-08 Acushnet Company Sulfur-containing composition for golf equipment, and method of using same
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
JP2010507648A (ja) 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
DK3564674T3 (da) * 2006-11-01 2021-10-18 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til fremstilling og anvendelse deraf
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
JP5450092B2 (ja) 2006-12-29 2014-03-26 アボット・ラボラトリーズ 全血中の分子または薬物の検出のための診断検査
CN100482643C (zh) * 2007-01-19 2009-04-29 中国科学院广州生物医药与健康研究院 一种氨基脲衍生物及其单克隆抗体与应用
CN101091700B (zh) * 2007-07-03 2011-06-08 上海现代药物制剂工程研究中心有限公司 富马酸喹硫平缓控释制剂组合物及其制备用途
CN101809447A (zh) 2007-09-27 2010-08-18 诺瓦提斯公司 药物监测方法
JP5828762B2 (ja) 2008-07-21 2015-12-09 プロビオドルグ エージー 診断用抗体アッセイ
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
CN102245605B (zh) 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
EP2347015A4 (en) * 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
WO2010083843A1 (en) * 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8913245B2 (en) 2010-06-29 2014-12-16 Kla-Tencor Corporation System and method for interferometric autofocusing
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102190724A (zh) * 2011-03-31 2011-09-21 上海大学 十氯酮抗原、抗体及其制备方法
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
CN104884438B (zh) 2012-08-16 2017-07-28 詹森药业有限公司 作为n型钙通道阻滞剂的取代的吡唑
WO2014031665A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine haptens and use thereof
AU2013305887B2 (en) 2012-08-21 2018-02-22 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
US9304126B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of quetiapine
ES2904838T3 (es) 2012-08-21 2022-04-06 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
WO2014031595A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of paliperidone
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
PL2888592T3 (pl) * 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
AU2013305895B2 (en) 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
JP6270845B2 (ja) 2012-08-21 2018-01-31 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールに対する抗体及びその使用
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
EP3492473B1 (en) 2012-08-21 2025-07-30 Janssen Pharmaceutica NV Haptens of olanzapine
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN108368180B (zh) * 2015-12-17 2022-07-26 詹森药业有限公司 喹硫平的抗体及其用途

Also Published As

Publication number Publication date
PL3663317T3 (pl) 2023-06-05
PT3663317T (pt) 2023-01-23
WO2014031665A1 (en) 2014-02-27
AU2013305904B2 (en) 2017-08-17
EP2888286A1 (en) 2015-07-01
EP2888286A4 (en) 2016-03-23
US9850318B2 (en) 2017-12-26
EP3663317B1 (en) 2022-10-12
AU2013305904A1 (en) 2015-03-05
EP3663317A1 (en) 2020-06-10
JP2015529203A (ja) 2015-10-05
PT3385284T (pt) 2020-05-20
US20180105606A1 (en) 2018-04-19
ES2664952T3 (es) 2018-04-24
PT2888286T (pt) 2018-05-09
HK1211959A1 (en) 2016-06-03
CA2882597C (en) 2020-04-14
JP2019073513A (ja) 2019-05-16
US20200040107A1 (en) 2020-02-06
CN104736564A (zh) 2015-06-24
US20210017294A9 (en) 2021-01-21
EP3385284A1 (en) 2018-10-10
CA2882597A1 (en) 2014-02-27
PL2888286T3 (pl) 2018-07-31
JP6450314B2 (ja) 2019-01-09
EP3385284B1 (en) 2020-02-26
AU2017261579A1 (en) 2017-12-07
AU2017261579B2 (en) 2019-11-07
CN110054693A (zh) 2019-07-26
ES2788716T3 (es) 2020-10-22
US20140057305A1 (en) 2014-02-27
JP6637580B2 (ja) 2020-01-29
EP2888286B1 (en) 2018-02-21
CN104736564B (zh) 2019-02-05
US10465013B2 (en) 2019-11-05
ES2935460T3 (es) 2023-03-07

Similar Documents

Publication Publication Date Title
PL2888286T3 (pl) Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL2888284T3 (pl) Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
PT2887952T (pt) Anticorpos para haptenos da olanzapina e suas utilizações
PL3333195T3 (pl) Przeciwciała względem kwetiapiny i ich zastosowania
IL238559A0 (en) Antibodies against ceacam5 and their use
PL3462173T3 (pl) Przeciwciała przeciwko rysperydonowi i ich zastosowanie
EP2888287A4 (en) ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
PL2888257T3 (pl) Hapteny kwetiapiny do zastosowania w testach immunologicznych
PT2888590T (pt) Anticorpos para olanzapina e utilização destes
IL254416A0 (en) Anti-asic1 antibodies and their uses
PL3354751T3 (pl) Przeciwciała dla arypiprazolu i ich zastosowanie
EP2888277A4 (en) ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
IL238366A0 (en) Antibodies to interleukin-6 and their uses
GB201208372D0 (en) Antibodies and uses thereof